N Engl J Med. The median follow-up duration was 58 months 4. Analysis was by intention-to-treat. The primary, secondary, and tertiary adjudicated endpoint analyses were validated by the data monitoring committee independent statistician. Offer good through December 31, Overall adverse event rates were similar across treatment groups.
|Published (Last):||7 October 2008|
|PDF File Size:||15.29 Mb|
|ePub File Size:||5.58 Mb|
|Price:||Free* [*Free Regsitration Required]|
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients JELIS : a randomised open-label, blinded endpoint analysis. Author information: 1 Kobe University, Kobe, Japan. Comment in Lancet. Nat Clin Pract Cardiovasc Med. Evid Based Med. We aimed to test the hypothesis that long-term use of eicosapentaenoic acid EPA is effective for prevention of major coronary events in hypercholesterolaemic patients in Japan who consume a large amount of fish.
The primary endpoint was any major coronary event, including sudden cardiac death, fatal and non-fatal myocardial infarction, and other non-fatal events including unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting. Analysis was by intention-to-treat. The study was registered at ClinicalTrials. Serum LDL cholesterol was not a significant factor in a reduction of risk for major coronary events.
Unstable angina and non-fatal coronary events were also significantly reduced in the EPA group. Sudden cardiac death and coronary death did not differ between groups.
Japan EPA Lipid Intervention Study - JELIS
Worldwide, cardiovascular disease CVD remains the 1 killer of men and women. Vascepa is not fish oil, but is derived from fish through a stringent and complex FDA -regulated manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient. The effect of Vascepa on the risk for pancreatitis and cardiovascular mortality and morbidity in patients with severe hypertriglyceridemia has not been determined. Patients receiving treatment with Vascepa and other drugs affecting coagulation e. Patients should be advised to swallow Vascepa capsules whole; not to break open, crush, dissolve, or chew Vascepa. Nothing in this press release should be construed as promoting the use of Vascepa in any indication that has not been approved by the FDA. Important Cautionary Information About Topline Results Existing and prospective investors are cautioned not to place undue reliance on topline results.
Omega-3-Fettsäuren (EPA, DHA)